Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuela Albertelli

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Journal of Endocrinological Investigation|October 12, 2024
Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM)Francesco Panzuto, Manuela Albertelli, Maria Luisa De Rimini, et al.
Nutrients|July 27, 2022
Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement DoseElisa Marabotto, Diego Ferone, Afscin Djahandideh Sheijani, et al.
Oncotarget|April 29, 2017
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?Amira Mohamed, David Romano, Alexandru Saveanu, et al.
Endocrine-Related Cancer|July 12, 2014
Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor culturesAmira Mohamed, Marie-Pierre Blanchard, Manuela Albertelli, et al.
The Oncologist|March 13, 2020
Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter StudyNicole Brighi, Francesco Panzuto, Roberta Modica, et al.
Journal of Endocrinological Investigation|November 12, 2025
The clinical challenge of MEN1 phenocopies: insights from a multicentric national retrospective studyRosaria M Ruggeri, Elio Benevento, Iderina Hasballa, et al.
Endocrine|May 30, 2020
Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspectiveGiovanna Muscogiuri, Barbara Altieri, Manuela Albertelli, et al.
Endocrine Pathology|April 11, 2025
Multicentric Retrospective Analysis of Oncocytic Adrenocortical Carcinoma: Insights into Clinical and Management StrategiesAntonio Prinzi, Valentina Guarnotta, Guido Di Dalmazi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 7, 2025
AIMN, ITANET, SIE joint position paper for the recognition, prevention and management of NET carcinoid syndrome and crises during peptide receptor radionuclide therapyRiccardo Laudicella, Antongiulio Faggiano, Valeria Pirro, et al.
The Journal of Clinical Endocrinology and Metabolism|September 24, 2019
Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine TumorGiuseppe Lamberti, Antongiulio Faggiano, Nicole Brighi, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Journal of Endocrinological Investigation|October 12, 2024
Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM)Francesco Panzuto, Manuela Albertelli, Maria Luisa De Rimini, et al.
Nutrients|July 27, 2022
Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement DoseElisa Marabotto, Diego Ferone, Afscin Djahandideh Sheijani, et al.
Oncotarget|April 29, 2017
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?Amira Mohamed, David Romano, Alexandru Saveanu, et al.
Endocrine-Related Cancer|July 12, 2014
Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor culturesAmira Mohamed, Marie-Pierre Blanchard, Manuela Albertelli, et al.
The Oncologist|March 13, 2020
Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter StudyNicole Brighi, Francesco Panzuto, Roberta Modica, et al.
Journal of Endocrinological Investigation|November 12, 2025
The clinical challenge of MEN1 phenocopies: insights from a multicentric national retrospective studyRosaria M Ruggeri, Elio Benevento, Iderina Hasballa, et al.
Endocrine|May 30, 2020
Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspectiveGiovanna Muscogiuri, Barbara Altieri, Manuela Albertelli, et al.
Endocrine Pathology|April 11, 2025
Multicentric Retrospective Analysis of Oncocytic Adrenocortical Carcinoma: Insights into Clinical and Management StrategiesAntonio Prinzi, Valentina Guarnotta, Guido Di Dalmazi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 7, 2025
AIMN, ITANET, SIE joint position paper for the recognition, prevention and management of NET carcinoid syndrome and crises during peptide receptor radionuclide therapyRiccardo Laudicella, Antongiulio Faggiano, Valeria Pirro, et al.
The Journal of Clinical Endocrinology and Metabolism|September 24, 2019
Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine TumorGiuseppe Lamberti, Antongiulio Faggiano, Nicole Brighi, et al.
Pageof 7